Key Highlights

  • Effective on the designated trading day, the company will list under the new ticker on Nasdaq Capital Market.
  • The CUSIP for the common stock remains 949503205, preserving continuity for existing shareholders.
  • Upcoming milestone: commencement of trading under the new ticker.

Wellgistics Health (NASDAQ: WGRX) has completed a corporate rebrand, moving to the name DataMeds AI, Inc. and adopting a new market symbol on the Nasdaq Capital Market, effective at the opening of trading on the scheduled date. The shift does not modify shareholder rights, and no additional action is required from investors.

By aligning its identity with an AI‑focused health‑data platform, the company aims to sharpen its market positioning within the health‑technology sector.

Name and Symbol Update

The Delaware Secretary of State received a Certificate of Amendment, replacing the original corporate name with DataMeds AI, Inc. Concurrently, the firm announced that the new ticker will debut on the Nasdaq Capital Market. The CUSIP 949503205 stays unchanged, preserving the existing security identifier for all market participants.

No shareholder vote beyond the statutory approval was needed, and the amendment became effective at the start of the trading day, ensuring a smooth transition for market orders. This continuity safeguards existing holdings while introducing a more descriptive market symbol that reflects the company’s AI‑driven strategy.

Mechanics of the Amendment

The amendment process followed the relevant provisions of the Delaware General Corporation Law, with the board securing the requisite shareholder approvals before filing. The amendment substitutes the original corporate name in the Amended and Restated Certificate of Incorporation with the new name, formalizing the rebrand. The filing date establishes the legal effectiveness, while the public announcement was disseminated through a press release.

The release, issued from 3000 Bayport Drive, Suite 950 in Tampa, Fla. Lists James Lambert of Rubenstein Public Relations as the contact, reachable at 212.805.3024.

By preserving the CUSIP and executing the amendment promptly, the company minimizes disruption to trading and ensures compliance with Nasdaq listing standards.

Market Context and Sector Outlook

The rebrand occurs amid a dynamic environment where health‑technology firms are increasingly integrating artificial intelligence to enhance data analytics, patient engagement, and clinical decision support. While specific price metrics are not disclosed, the transition aligns the company with peers that emphasize AI capabilities as a core differentiator. Industry observers note that a clear brand narrative can aid investor understanding, particularly as capital markets evaluate the growth potential of AI‑centric health platforms.

The company’s continued focus on expanding its technology suite, including mobile health applications and AI‑driven diagnostic tools, positions it to capitalize on emerging demand for integrated digital health solutions.

Upcoming Milestones

The immediate catalyst is the activation of trading under the new ticker on the designated day, marking the first public display of the rebranded shares. Subsequent milestones include the rollout of the “Health Lives Here” mobile application and the expansion of the EinsteinRx AI platform into broader medical and laboratory domains, as outlined in the company’s forward‑looking statements. Investors are encouraged to monitor the opening price on the first day of trading for insights into market reception, as it may set the tone for near‑term liquidity and valuation.

Because the name change does not affect shareholder rights, the primary considerations revolve around the execution of the technology roadmap and the ability to generate sustainable revenue under the DataMeds AI brand.

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.